US20020051823A1 - Nanosilver-containing antibacterial and antifungal granules and methods for preparing and using the same - Google Patents
Nanosilver-containing antibacterial and antifungal granules and methods for preparing and using the same Download PDFInfo
- Publication number
- US20020051823A1 US20020051823A1 US09/840,906 US84090601A US2002051823A1 US 20020051823 A1 US20020051823 A1 US 20020051823A1 US 84090601 A US84090601 A US 84090601A US 2002051823 A1 US2002051823 A1 US 2002051823A1
- Authority
- US
- United States
- Prior art keywords
- solution
- nag
- nags
- nanosilver particles
- nanosilver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KKQGDMYVCFYDAO-UHFFFAOYSA-N C.C.C.C.SCS.[Ag]=[SH]C[SH]=[Ag] Chemical compound C.C.C.C.SCS.[Ag]=[SH]C[SH]=[Ag] KKQGDMYVCFYDAO-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to nanosilver particles-containing antibacterial and antifungal granules (NAGs).
- the nanosilver particles are attached to the surfaces and pores of stalk marrow of Juncus effuses L , which acts as an inert carrier for nanosilver.
- Each of the nanosilver particles contains a metallic silver core which is surrounded by silver oxide.
- the size of the nanosilver particle is between 1-100 nm in diameter.
- the present invention also relates to methods for preparing the NAGs and for using the NAGs.
- the NAGs can be used in a variety of healthcare, medicinal and industrial products.
- Silver is generally a safe and effective antimicrobial metal.
- Silver ions function in adversely affecting cellular metabolism to inhibit bacterial cell growth. When silver ions are absorbed into bacterial cells, silver ions suppress respiration, basal metabolism of the electron transfer system, and transport of substrate in the microbial cell membrane. Silver ions also inhibit bacterial growth by producing active oxygen on the surface of silver powder and silver-plated articles. Silver has been studied for antibacterial purposes in the form of powder, metal-substituted zeolite, metal-plated non-woven fabric, and crosslinked compound.
- U.S. Pat. No. 5,785,972 discloses a therapeutically active composition
- a therapeutically active composition comprising a solution of colloidal silver, helichrysum angustifolium or helichrysum italicum oil, and raw honey emulsified with water soluble lecithin.
- the contact between microbial cells and silver ions is not ensured as the silver ions quickly become eluted in the solution.
- Silver ions in solution are difficult to handle and therefore of limited use.
- U.S. Pat. No. 5,709,870 discloses a silver-containing antimicrobial agent comprising a silver salt of carboxymethylcellulose and having a degree of substitution of carboxymethyl group of not less than 0.4.
- Chinese Patent No. 87100231A discloses an antibacterial dressing made from nitrilon crosslinked with copper salts in alkaline medium. The resulted cloth shows antibacterial activity on ten (10) bacteria including Staphylococcus aureus (MRSA).
- MRSA Staphylococcus aureus
- Japan Process Technique Vol. 17, No. 7, teaches a nitrilon fiber manufactured from copper and sulfur salts.
- the fiber has bacteriostatic effects on Escherichia coli, Staphylococcus aureus, Bacillus subtilis , and Epidennophyton.
- Japanese Patent No. 3-136649 discloses an anti-bacterial cloth used for washing breasts of milk cow.
- the Ag + ions in AgNO 3 were crosslinked with polyacrylonitrile and it had anti-bacterial activity on six (6) bacteria including Streptococcus and Staphylococcus.
- Japanese Patent No. 54-151669 discloses a fiber treated with a solution of a compound of copper and silver. The solution is evenly distributed on the fiber. The fiber is used as an anti-bacterial lining inside boots, shoes, and pants.
- U.S. Pat. No. 4,828,832 discloses a composition for treating skin lesions which is made up of metallic silver particles having a diameter of 1 to 10 ⁇ m and an optional oxidizing agent randomly disbursed within a carrier of inert filler such as kaolin or talc.
- U.S. Pat. No. 5,824,267 discloses a plastic material having a bactericidal surface on which a number of ceramic or base metal particles of a mean diameter of 0.01 to 0.5 ⁇ m are embedded under the condition that a portion of each particle is exposed over the surface, and the ceramic or base metal particles have bactericidal metal particles of mean diameter of 0.0001 to 0.1 ⁇ m dispersively fixed thereon.
- Such solid supports using synthetic polymer materials have been not widely adapted for medical and healthcare purposes. These materials usually require bonding or cross-linking of the silver or silver ions to the polymers. Such bonding or cross-linking may invoke allergic reactions in patients. These materials also do not have sufficiently high antibacterial activity due to the lack of sufficient surface contact with the bacteria. Additionally, the bactericidal activity of these materials rapidly diminishes as the silver ions become separated from the solid supports, thus, these materials do not show bactericidal activity over a prolonged period of time. Lastly, the processes for making these materials are complicated and time-consuming.
- the present invention provides nanosilver-containing antibacterial and antifungal granules (NAGs).
- the NAGs are made of stalk marrow of Juncus effuses L. (as a carrier) with nanosilver particles evenly dispersed on the surfaces and pores of the stalk marrow. These NAGs display longlasting bactericidal and fungicidal activities.
- the NAGs of the present invention are safe to use for medical and healthcare purposes as well as used in industrial products.
- the present invention also provides a method for making the NAG which is suitable and feasible for large scale industrial production.
- the present invention is an improvement over Chinese Patent Nos. CN 1034090, CN 1093004, and CN 1123665, which are herein incorporated by reference.
- CN 1034090 discloses a method of attaching nanosilver particles to textile.
- CN 1093004 discloses a suture or medical thread containing nanosilver particles.
- CN 1123665 discloses a granule containing nanosilver particles attached to stalk marrow which can be used to disinfect tooth brush, for treatment of acne and pimples, and as cleansing agents to prevent gynecological infections such as vaginitis.
- the method for making the NAGs and the utility of using the NAGs described in the present invention are different from those described in CN 1034090, CN 1093004, and CN 1123665.
- the present invention provides nanosilver-containing antibacterial and antifiungal granules (NAGS) which comprise nano silver particles which are firmly and evenly attached to stalk marrow of Juncus effuses L .
- the nanosilver particles are about 1-100 nm in diameter.
- the individual nanosilver particle has a metallic silver core surrounded by silver oxide.
- the NAGs display longstanding inhibitory effect on a broad spectrum of bacteria and fungi.
- bacteria and fungi include, but are not limited to, Escherichia coli, Methicillin resistant Staphylococcus aureus, Chlamydia trachomatis, Providencia stuartii, Vibrio vulnificus , Pneumobacillus, Nitrate-negative bacillus, Staphylococcus aureus, Candida albicans, Bacillus cloacae, Bacillus allantoides, Morgan's bacillus ( Salmonella morgani ), Pseudomonas maltophila, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Bacillus subtilis, Bacillus foecalis alkaligenes, Streptococcus hemolyticus B , Citrobacter, and Salmonella paratyphi C.
- the NAGs are produced by (1) cutting the stalk marrow of Junicus effuses L . into pieces; (2) immersing the cut stalk marrow in a solution containing nanosilver particles to allow the attachment of the nanosilver particles to the cut stalk marrow; (3) after the attachment, drying the nanosilver particles-attached stalk marrow; and (4) grinding the nanosilver particles-containing stalk marrow to appropriate size to produce the NAGs. Before drying the nanosilver particles-containing stalk marrow, the stalk marrow is optionally washed with hot and cold water.
- the nanosilver particles are made by dissolving silver nitrate in a solution containing concentrated ammonia water, glucose or ascorbic acid (as reducing agent), and an oxidizing agent.
- a solution containing concentrated ammonia water, glucose or ascorbic acid (as reducing agent), and an oxidizing agent can be added to the solution to adjust the pH, and ethanol can be added to the solution to improve the solubility of the solution.
- the preferred oxidizing agent is hydrogen peroxide (H 2 O 2 ).
- the present invention also provides a method for preparing the NAGs.
- the method comprises the following steps: (1) cutting the stalk marrow of Junicus effuses L , into pieces (about 0.5 to 2 cm at length); (2) preparing a nanosilver particles-containing solution; (3) immersing and thoroughly mixing the cut stalk marrow pieces in the nanosilver particles-containing solution to allow the attachment of the nanosilver particles to the cut stalk marrow pieces; (4) washing the cut stalk marrow pieces (preferably first with hot water, then with cold water); (5) drying the cut stalk marrow pieces; and (6) grinding the dried cut stalk marrow pieces to the desirable size(s) of the NAGs.
- the NAGs have a size which is capable of passing through a No. 200 sieve. It is preferred to boil the cut stalk marrow pieces to remove unwanted water-soluble materials, followed by heat drying the boiled stalk marrow pieces, before soaking the stalk marrow pieces in the nanosilver particle-containing solution. It is also preferred to treat the nanosilver soaked stalk marrow pieces with heat until the stalk marrow pieces turn brown, before washing the stalk marrow pieces with hot and cold water.
- the nanosilver solution is prepared by the following step-wise procedure: (1) dissolving silver nitrate (AgNO 3 ) crystal in a concentrated ammonia water solution; (2) adding glucose or ascorbic acid (as reducing agent) to the solution; and (3) adding an oxidizing agent to the solution.
- the preferred oxidizing agent is hydrogen peroxide (H 2 O 2 ).
- NaOH and ethanol can be added to the nanosilver solution to adjust the pH and improve the solubility of the nanosilver solution, respectively.
- the present invention provides methods of using the NAGs.
- the NAGs can be used in a variety of healthcare, medicinal, and industrial products.
- the NAGs can be added to ointments, lotions, and/or solutions for treating humans or animals with skin trauma, such as acne or pimples, wound, burns, skin with bacterial or fungal infections.
- the NAGs can be used in hygiene products, such as women gynecological washing solution, tooth brush soaking solution, or facial cleansing solution.
- the NAGs can also be used as food preservatives (e.g., for preserving fruits and vegetables), water disinfectants, paper disinfectants (e.g., for preventing mold build-up in book, newspaper, certificate, envelope, stationary, money, paper food containers, etc.), and in construction filling materials to prevent mold formation.
- food preservatives e.g., for preserving fruits and vegetables
- paper disinfectants e.g., for preventing mold build-up in book, newspaper, certificate, envelope, stationary, money, paper food containers, etc.
- construction filling materials to prevent mold formation.
- the NAGs can be used as medicines to treat patients with gastrointestinal infection, sexually transmitted diseases, and eye diseases.
- FIG. 1 shows the inhibitory effect of the NAGs on Staphylococcus aureus .
- the horizontal axis of the curve is the treatment time, the vertical axis is the amount of the bacteria remained (measured by CFU (colony forming units)) after being immersed in the NAGs-containing solution.
- Open circle indicates no NAGs. Close circle indicates with NAGs.
- FIG. 2 shows the inhibitory effect of the NAGs on Escherichia coli .
- the horizontal axis of the curve is the treatment time, the vertical axis is the amount of the bacteria remained (measured by CFU (colony forming units)) after being immersed in the NAGs-containing solution. Open circle indicates no NAGs. Close circle indicates with NAGs.
- FIG. 3 shows the inhibitory effect of the NAGs on Pseudomonas aeruginosa .
- the horizontal axis of the curve is the treatment time, the vertical axis is the amount of the bacteria remained (measured by CFU (colony forming units)) after being immersed in the NAGs-containing solution. Open circle indicates no NAGs. Close circle indicates with NAGs.
- FIG. 4 is a flow chart indicating the process for making the NAGs in an industrial scale manufacturing.
- chambers which are: (1) selection chamber; (2) separation chamber; (3) spraying chamber; (4) water removal chamber; (5) heat reaction chamber; (6) washing and soaking chamber; (7) drying chamber; and (8) grinding chamber.
- the function of each chamber will be described in the following section (infra).
- the present invention is directed to sustained-effect, broad-spectrum nanosilver containing antibacterial and antifungal granules (NAGs) and the process of manufacturing and using NAGs.
- the NAGs of the present invention are made by attaching nanosilver particles to small pieces of stalk marrow of the plant Juncus effuses L .
- the attachment of nanosilver particles to the NAGs have been confirmed by scanning electromicroscopy using AMRAY1910FE and TN-8502, which shows that the nanosilver particles on the NAGs were about 25 nm in diameter.
- the nanosilver particles were shown evenly distributed on the NAGs.
- the content of the nanosilver particles in the NAGs were analyzed by silver titrimetric method (see infra) to contain about 20-100 mg of silver per g of the NAGs. Also, due to the fact that the surface of the nanosilver particles was dark brown, which is a characteristic of silver oxidation, the surface of the nanosilver particles were identified to be silver oxide.
- Juncus or rush pith “Deng Xin Cao” in Chinese, has the pharmaceutical name Medulla Junci effusi , botanical name Juncus effusus L . var. decipiens Buchen .
- the plant belongs to the family of Juncaceae and is grown in the provinces of Jiangsu, Sichuan, Yunnan, and Guizhou in China. Juncus is harvested at the end of summer through autumn. There is no known major active ingredients in the plant. Because of its inert characteristics, the stalk marrow of Juncus is suitable for use as a carrier for nanosilver particles.
- the NAGs of the present invention have demonstrated high antibacterial and antifungal effects. They are also non-toxic, non-stimulative, and non-allergic, so that they can be safely used in a large variety of healthcare, medicinal, and industrial products.
- AgNO3+reducing agent Glucose or Ascorbic Acid
- Silver ion is an effective antiseptic and germicide, and its organic salts, particularly in the form of nitrates, are commonly used with furazolidones and antibiotics in the treatment of bums.
- Silver nitrate is one of the most powerful chemical germicides and is widely used as a local astringent and germicide. However, the nitrates irritate the skin.
- the metallic silver as demonstrated in the second (2) reaction, is then undergone an oxidation to produce silver oxide (Ag 2 O) in the presence of an oxidizing agent.
- the NAGs has a broad spectrum of antibacterial and antifungal activity.
- the NAGs of the present invention had bactericidal and fungicidal effects on more than twenty (20) common pathogens, which include, but are not limited to, Escherichia coli, Methicillin resistant Staphylococcus aureus, Chlamydia trachomatis, Providencia stuartii, Vibrio vulnificus , Pneumobacillus, Nitrate-negative bacillus, Staphylococcus aureus, Candida albicans, Bacillus cloacae, Bacillus allantoides, Morgan's bacillus ( Salmonella morgani ), Pseudomonas altophila , Arizona, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Bacillus subtilis, Bacillus foecalis alkaligenes, Streptococcus hemolyticus B
- FIGS. 1 - 3 Examples of the antibacterial activity of the NAGs were demonstrated in FIGS. 1 - 3 .
- FIG. 1 shows the effect of the NAGs on Staphylococcus aureus . The data demonstrate that within 8 hours of treatment with the NAGs, all of the S. aureus were killed.
- FIG. 2 shows the effect of the NAGs on Escherichia coli . The data also demonstrate that within 8 hours of treatment with the NAGs, all of the E. coli were killed.
- FIG. 3 shows the effect of the NAGs on Pseudomonas aeruginosa . The data show that within 12 hours of treatment with the NAGs, all of the P. aeruginosa were killed.
- the NAGs were prepared by first cutting the stalk marrow of Juncus effuses L . into pieces of 0.5 to 2 cm at length. These small pieces of stalk marrow were washed, followed by boiling in water to remove any unwanted water soluble materials. The boiled stalk marrow pieces were than dried for later use.
- a nanosilver particles-containing solution was prepared by first dissolving AgNO 3 in ammonia water, followed by adding glucose (as reducing agent) to the reaction solution. An oxidizing agent, preferably H 2 O 2 , was then added to the reaction solution.
- the quantity or volume of each of the ingredients used in the nanosilver particle-containing solution is listed in Table 1.
- Nanosilver Particles-Containing Solution Ingredients Quantity or Volume AgNO 3 15 Kg Ammonia Water 15 L Glucose 3 Kg Ethanol (95%) 5 L NaOH 0.5 Kg Oxidizing Agent (e.g., H 2 O 2 ) 100 ml Distilled Water up to 1000 L
- FIG. 4 shows a flow chart of industrial production of the NAGs. The process was operated in the following chambers: (1) selection chamber; (2) separation chamber; (3) spraying chamber; (4) water removal chamber; (5) heat reaction chamber; (6) washing and soaking chamber; (7) drying chamber; and (8) grinding chamber.
- stalk marrow of Juncus effuses L were cut into pieces, preferably at a length of about 0.5 to 2 cm.
- the small pieces of stalk marrow were sieved through a selection process and transferred to the “separation” chamber, where the stalk marrow pieces were boiled and dried.
- the small pieces of dried stalk marrow were then transferred to the “spraying” chamber where the nanosilver particles-containing solution was evenly sprayed and dispersed onto the small pieces of dried stalk marrow.
- the small pieces of stalk marrow were further soaked with the nanosilver particles-containing solution in the “spraying” chamber for an adequate amount of time.
- the small pieces of stalk marrow with attached nanosilver particles were then transferred to the “water removal” chamber where excess solution was removed from the pieces.
- the heat-reacted stalk marrow pieces were transferred to the “soaking and washing” chamber, where the pieces were soaked and washed first with hot water, then with cold water, to remove any unattached nanosilver particles and water-soluble substances.
- the washed nanosilver particles-attached stalk marrow pieces were then dried under heat in the “drying” chamber, and finally transferred to the “grinding” chamber to be ground to proper NAG sizes.
- the final NAGs should contain no water-soluble substances other than silver.
- Examples of the NAGs used in healthcare products include, but are not limited to, ointments, lotions, or spraying solutions for treating all kinds of injuries and/or bums, bacterial and fungal infections (including gynecological infections such as vaginitis), cleansing agents for clothing, women hygiene, acne or pimples, and soaking solution for tooth brush.
- Examples of the NAGs used in medicinal products include, but are not limited to, internal medicines for treating gastrointestinal bacterial infection, sexually transmitted diseases, or as an eye drop for treating eye diseases.
- Examples of the NAGs used in industrial products include, but are not limited to, food preservatives especially for fruits and vegetables, drinking water disinfectants, paper and construction filling materials preservation (especially to prevent mold formation).
- Solvent HNO 3 solution.
- the solution was prepared by mixing nitric acid with water at ratio 1:1 (v/v).
- the concentration of nitric acid in the solution was 6N.
- T Ag Ag amount in Ag standard solution/[(mean volume of the triplicates)-blank](The unit for T Ag is mg/ml.)
- V was the volume of the NH 4 SCN solution added to the titration flask after the blank was deducted.
- T Ag was in the unit of mg Ag/ml.
- W was the weight of the NAG sample in mg.
- the silver content of the NAGs was about 2-8%.
- NAGs-containing solution Five (5) g of the NAGs were suspended in 500 ml of water and stayed in the solution for 24 hrs to obtain an NAGs-containing solution.
- M-H liquid and solid culture media were used for activation and culture of the bacteria.
- Staphylococcus aureus stock M120, Escherichia coli stock E109, and Pseudomonas aeruginosa stock PS208 were used for the testing. These stocks were provided by the Microbiology Teaching and Research Section at Henan Medical University.
- the frozen stocks of bacteria were seeded onto solid culture media. Single colonies were picked and inoculated respectively in 2 ml liquid culture medium and cultured at 37° C. for eight (8) hours. Then, the liquid culture medium was diluted at 1:1000 and stored in refrigerator (around 0° C.) until ready for use. The solution contained about 10 5 CFU/ml bacterial stock.
- the NAGs-containing solution was added to three (3) flasks, each containing 100 ml of the solution.
- One (1) ml of the bacterial stocks of E. coli, S. aureus , or P. aeruginosa was then added to the three flasks, respectively.
- the control was prepared by adding the bacterial stocks in the flasks containing water.
- the inhibitory effect of the NAGs on the three different bacteria was conducted over a period of eight (8) hours.
- the solution was diluted and plated on a culture plate to measure the number of remaining bacteria.
- the solution containing the NAGs more than 99% of all the tested bacteria were killed, which demonstrated that the NAGs-containing solution was very effective as bactericide and could be used as disinfectant.
- M-H liquid and solid culture media were used for activation and culture of the bacteria.
- Staphylococcus aureus stock M120, Escherichia coli stock E109, and Pseudomonas aeruginosa stock PS208 were provided by the Microbiology Teaching and Research Section at Henan Medical University. The stocks were cultured in an incubator at 37° C. for 24 hours.
- the frozen stocks of bacteria were seeded to a culture plate. Single colonies were chosen and inoculated in 2 ml liquid culture medium, respectively, where they were cultured at 37° C. for eight (8) hours. Then, the liquid culture medium was diluted at 1:1000 and stored in the refrigerator (around 0° C.) until ready for use. The solution contained about 10 5 CFU/ml bacterial stock.
- Staphylococcus aureus stock M120 was provided by the Microbiology Teaching and Research Section at Henan Medical University. The stock was cultured in an incubator at 37° C. for 24 hours.
- the frozen stock of bacteria was seeded to a culture plate. A single colony was chosen and inoculated in 2 ml liquid culture medium, respectively, where the bacteria were cultured at 37° C. for eight (8) hours. Then, the liquid culture medium was diluted at 1:1000 and stored in the refrigerator (around 0° C.) until ready for use. The solution contained about 10 5 CFU/ml bacterial stock.
- a half of a toothbrush was immersed in 30 ml of a solution containing the NAGs for eight (8) hours.
- the other half of the toothbrush was immersed in 30 ml of saline solution.
- One (1) ml of each of the solutions was taken out after the 8 hours incubation, diluted, and tested for bacteria counts on plate. This method tested the natural existence of germs on the toothbrush and the effect of the NAGs on inhibiting the growth of the germs.
- a half of the toothbrush was immersed in 30 ml solution containing the NAGs.
- One (1) ml of the bacterial stock containing Staphylococcus aureus was added to the solution. At the end of the 8 hours incubation, 1 ml of the solution was taken out and tested for bacteria counts on plate.
- the other half of the toothbrush was immersed in 30 ml of saline solution.
- One (1) ml of each of the solutions was taken out after the 8 hours incubation, diluted, and tested for bacteria counts on plate. This method tested the bactericidal effect of the NAGs on toothbrush where known amount of S. aureus was inoculated in the solution
- the bactericidal efficiency for the NAGs was about 95%.
- the bactericidal efficiency for the NAGs was about 98%.
- the NAGs were given to normal, healthy rats in a dose of 925 mg/kg of body weight per day for fourteen (14) days. This dose was more than 4,625 fold of the dose generally recommended to humans. The activities of rats were monitored. At the end of the 14 days period, no rats were dead or sick, which indicated that the NAGs were safe and non-toxic to rats.
- a 5% (w/v) NAGs-containing solution was applied to the skin of the rabbits.
- the rabbits were monitored at 1 hr, 24 hrs, and 48 hrs intervals. No rash, bruise, or any irritating reaction was observed on the rabbit skins, which indicated that the NAGs were safe and not creating any allergic reaction on the skins.
Abstract
Description
- This application claims the priority of U.S. Provisional Application No. 60/230,925, filed on Sep. 13, 2000, which is herein incorporated by reference.
- The present invention relates to nanosilver particles-containing antibacterial and antifungal granules (NAGs). The nanosilver particles are attached to the surfaces and pores of stalk marrow ofJuncus effuses L, which acts as an inert carrier for nanosilver. Each of the nanosilver particles contains a metallic silver core which is surrounded by silver oxide. The size of the nanosilver particle is between 1-100 nm in diameter. The present invention also relates to methods for preparing the NAGs and for using the NAGs. The NAGs can be used in a variety of healthcare, medicinal and industrial products.
- Metals including silver, copper, mercury, and zinc are known for anti-bacterial properties. Bacteria treated by these metals do not acquire resistance to the metals. Therefore, the bactericidal metals have advantages over the conventional antibiotics which often cause the selection of antibiotic-resistant microorganism.
- Silver is generally a safe and effective antimicrobial metal. Silver ions function in adversely affecting cellular metabolism to inhibit bacterial cell growth. When silver ions are absorbed into bacterial cells, silver ions suppress respiration, basal metabolism of the electron transfer system, and transport of substrate in the microbial cell membrane. Silver ions also inhibit bacterial growth by producing active oxygen on the surface of silver powder and silver-plated articles. Silver has been studied for antibacterial purposes in the form of powder, metal-substituted zeolite, metal-plated non-woven fabric, and crosslinked compound.
- U.S. Pat. No. 5,785,972 discloses a therapeutically active composition comprising a solution of colloidal silver, helichrysum angustifolium or helichrysum italicum oil, and raw honey emulsified with water soluble lecithin. However, the contact between microbial cells and silver ions is not ensured as the silver ions quickly become eluted in the solution. Silver ions in solution are difficult to handle and therefore of limited use.
- To solve the problem in liquid state, various crosslinked agents and solid supports for silver ions have been developed. For example, U.S. Pat. No. 5,709,870 discloses a silver-containing antimicrobial agent comprising a silver salt of carboxymethylcellulose and having a degree of substitution of carboxymethyl group of not less than 0.4.
- Chinese Patent No. 87100231A discloses an antibacterial dressing made from nitrilon crosslinked with copper salts in alkaline medium. The resulted cloth shows antibacterial activity on ten (10) bacteria includingStaphylococcus aureus (MRSA).
- Japan Process Technique, Vol. 17, No. 7, teaches a nitrilon fiber manufactured from copper and sulfur salts. The fiber has bacteriostatic effects onEscherichia coli, Staphylococcus aureus, Bacillus subtilis, and Epidennophyton.
- Japanese Patent No. 3-136649 discloses an anti-bacterial cloth used for washing breasts of milk cow. The Ag+ ions in AgNO3 were crosslinked with polyacrylonitrile and it had anti-bacterial activity on six (6) bacteria including Streptococcus and Staphylococcus.
- Japanese Patent No. 54-151669 discloses a fiber treated with a solution of a compound of copper and silver. The solution is evenly distributed on the fiber. The fiber is used as an anti-bacterial lining inside boots, shoes, and pants.
- U.S. Pat. No. 4,828,832 discloses a composition for treating skin lesions which is made up of metallic silver particles having a diameter of 1 to 10 μm and an optional oxidizing agent randomly disbursed within a carrier of inert filler such as kaolin or talc.
- U.S. Pat. No. 5,824,267 discloses a plastic material having a bactericidal surface on which a number of ceramic or base metal particles of a mean diameter of 0.01 to 0.5 μm are embedded under the condition that a portion of each particle is exposed over the surface, and the ceramic or base metal particles have bactericidal metal particles of mean diameter of 0.0001 to 0.1 μm dispersively fixed thereon.
- Such solid supports using synthetic polymer materials have been not widely adapted for medical and healthcare purposes. These materials usually require bonding or cross-linking of the silver or silver ions to the polymers. Such bonding or cross-linking may invoke allergic reactions in patients. These materials also do not have sufficiently high antibacterial activity due to the lack of sufficient surface contact with the bacteria. Additionally, the bactericidal activity of these materials rapidly diminishes as the silver ions become separated from the solid supports, thus, these materials do not show bactericidal activity over a prolonged period of time. Lastly, the processes for making these materials are complicated and time-consuming.
- The present invention provides nanosilver-containing antibacterial and antifungal granules (NAGs). The NAGs are made of stalk marrow ofJuncus effuses L. (as a carrier) with nanosilver particles evenly dispersed on the surfaces and pores of the stalk marrow. These NAGs display longlasting bactericidal and fungicidal activities. The NAGs of the present invention are safe to use for medical and healthcare purposes as well as used in industrial products.
- The present invention also provides a method for making the NAG which is suitable and feasible for large scale industrial production. The present invention is an improvement over Chinese Patent Nos. CN 1034090, CN 1093004, and CN 1123665, which are herein incorporated by reference. CN 1034090 discloses a method of attaching nanosilver particles to textile. CN 1093004 discloses a suture or medical thread containing nanosilver particles. CN 1123665 discloses a granule containing nanosilver particles attached to stalk marrow which can be used to disinfect tooth brush, for treatment of acne and pimples, and as cleansing agents to prevent gynecological infections such as vaginitis. The method for making the NAGs and the utility of using the NAGs described in the present invention are different from those described in CN 1034090, CN 1093004, and CN 1123665.
- The present invention provides nanosilver-containing antibacterial and antifiungal granules (NAGS) which comprise nano silver particles which are firmly and evenly attached to stalk marrow ofJuncus effuses L. The nanosilver particles are about 1-100 nm in diameter. The individual nanosilver particle has a metallic silver core surrounded by silver oxide.
- The NAGs display longstanding inhibitory effect on a broad spectrum of bacteria and fungi. Examples of the bacteria and fungi include, but are not limited to,Escherichia coli, Methicillin resistant Staphylococcus aureus, Chlamydia trachomatis, Providencia stuartii, Vibrio vulnificus, Pneumobacillus, Nitrate-negative bacillus, Staphylococcus aureus, Candida albicans, Bacillus cloacae, Bacillus allantoides, Morgan's bacillus (Salmonella morgani), Pseudomonas maltophila, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Bacillus subtilis, Bacillus foecalis alkaligenes, Streptococcus hemolyticus B, Citrobacter, and Salmonella paratyphi C.
- The NAGs are produced by (1) cutting the stalk marrow ofJunicus effuses L. into pieces; (2) immersing the cut stalk marrow in a solution containing nanosilver particles to allow the attachment of the nanosilver particles to the cut stalk marrow; (3) after the attachment, drying the nanosilver particles-attached stalk marrow; and (4) grinding the nanosilver particles-containing stalk marrow to appropriate size to produce the NAGs. Before drying the nanosilver particles-containing stalk marrow, the stalk marrow is optionally washed with hot and cold water.
- The nanosilver particles are made by dissolving silver nitrate in a solution containing concentrated ammonia water, glucose or ascorbic acid (as reducing agent), and an oxidizing agent. Optionally, NaOH can be added to the solution to adjust the pH, and ethanol can be added to the solution to improve the solubility of the solution. The preferred oxidizing agent is hydrogen peroxide (H2O2).
- The present invention also provides a method for preparing the NAGs. The method comprises the following steps: (1) cutting the stalk marrow ofJunicus effuses L, into pieces (about 0.5 to 2 cm at length); (2) preparing a nanosilver particles-containing solution; (3) immersing and thoroughly mixing the cut stalk marrow pieces in the nanosilver particles-containing solution to allow the attachment of the nanosilver particles to the cut stalk marrow pieces; (4) washing the cut stalk marrow pieces (preferably first with hot water, then with cold water); (5) drying the cut stalk marrow pieces; and (6) grinding the dried cut stalk marrow pieces to the desirable size(s) of the NAGs. It is preferred that the NAGs have a size which is capable of passing through a No. 200 sieve. It is preferred to boil the cut stalk marrow pieces to remove unwanted water-soluble materials, followed by heat drying the boiled stalk marrow pieces, before soaking the stalk marrow pieces in the nanosilver particle-containing solution. It is also preferred to treat the nanosilver soaked stalk marrow pieces with heat until the stalk marrow pieces turn brown, before washing the stalk marrow pieces with hot and cold water.
- The nanosilver solution is prepared by the following step-wise procedure: (1) dissolving silver nitrate (AgNO3) crystal in a concentrated ammonia water solution; (2) adding glucose or ascorbic acid (as reducing agent) to the solution; and (3) adding an oxidizing agent to the solution. The preferred oxidizing agent is hydrogen peroxide (H2O2). Optionally, NaOH and ethanol can be added to the nanosilver solution to adjust the pH and improve the solubility of the nanosilver solution, respectively.
- Additionally, the present invention provides methods of using the NAGs. The NAGs can be used in a variety of healthcare, medicinal, and industrial products. The NAGs can be added to ointments, lotions, and/or solutions for treating humans or animals with skin trauma, such as acne or pimples, wound, burns, skin with bacterial or fungal infections. In addition, the NAGs can be used in hygiene products, such as women gynecological washing solution, tooth brush soaking solution, or facial cleansing solution. The NAGs can also be used as food preservatives (e.g., for preserving fruits and vegetables), water disinfectants, paper disinfectants (e.g., for preventing mold build-up in book, newspaper, certificate, envelope, stationary, money, paper food containers, etc.), and in construction filling materials to prevent mold formation. Finally, the NAGs can be used as medicines to treat patients with gastrointestinal infection, sexually transmitted diseases, and eye diseases.
- FIG. 1 shows the inhibitory effect of the NAGs onStaphylococcus aureus. The horizontal axis of the curve is the treatment time, the vertical axis is the amount of the bacteria remained (measured by CFU (colony forming units)) after being immersed in the NAGs-containing solution. Open circle indicates no NAGs. Close circle indicates with NAGs.
- FIG. 2 shows the inhibitory effect of the NAGs onEscherichia coli. The horizontal axis of the curve is the treatment time, the vertical axis is the amount of the bacteria remained (measured by CFU (colony forming units)) after being immersed in the NAGs-containing solution. Open circle indicates no NAGs. Close circle indicates with NAGs.
- FIG. 3 shows the inhibitory effect of the NAGs onPseudomonas aeruginosa. The horizontal axis of the curve is the treatment time, the vertical axis is the amount of the bacteria remained (measured by CFU (colony forming units)) after being immersed in the NAGs-containing solution. Open circle indicates no NAGs. Close circle indicates with NAGs.
- FIG. 4 is a flow chart indicating the process for making the NAGs in an industrial scale manufacturing. There are eight (8) chambers associated with the process, which are: (1) selection chamber; (2) separation chamber; (3) spraying chamber; (4) water removal chamber; (5) heat reaction chamber; (6) washing and soaking chamber; (7) drying chamber; and (8) grinding chamber. The function of each chamber will be described in the following section (infra).
- The present invention is directed to sustained-effect, broad-spectrum nanosilver containing antibacterial and antifungal granules (NAGs) and the process of manufacturing and using NAGs. The NAGs of the present invention are made by attaching nanosilver particles to small pieces of stalk marrow of the plantJuncus effuses L. The attachment of nanosilver particles to the NAGs have been confirmed by scanning electromicroscopy using AMRAY1910FE and TN-8502, which shows that the nanosilver particles on the NAGs were about 25 nm in diameter. The nanosilver particles were shown evenly distributed on the NAGs. The content of the nanosilver particles in the NAGs were analyzed by silver titrimetric method (see infra) to contain about 20-100 mg of silver per g of the NAGs. Also, due to the fact that the surface of the nanosilver particles was dark brown, which is a characteristic of silver oxidation, the surface of the nanosilver particles were identified to be silver oxide.
- Juncus or rush pith, “Deng Xin Cao” in Chinese, has the pharmaceutical nameMedulla Junci effusi, botanical name Juncus effusus L. var.decipiens Buchen. The plant belongs to the family of Juncaceae and is grown in the provinces of Jiangsu, Sichuan, Yunnan, and Guizhou in China. Juncus is harvested at the end of summer through autumn. There is no known major active ingredients in the plant. Because of its inert characteristics, the stalk marrow of Juncus is suitable for use as a carrier for nanosilver particles.
- The NAGs of the present invention have demonstrated high antibacterial and antifungal effects. They are also non-toxic, non-stimulative, and non-allergic, so that they can be safely used in a large variety of healthcare, medicinal, and industrial products.
- The antibactial and antifungal effects of the NAGs can be explained in the following four (4) chemical process:
- (1) AgNO3+reducing agent (Glucose or Ascorbic Acid)→Ag;
- (2) Ag+O2 (oxidizing agent) Ag2O;
-
- Silver ion is an effective antiseptic and germicide, and its organic salts, particularly in the form of nitrates, are commonly used with furazolidones and antibiotics in the treatment of bums. Silver nitrate is one of the most powerful chemical germicides and is widely used as a local astringent and germicide. However, the nitrates irritate the skin. Thus, it is preferable to reduce the silver nitrate to metallic silver in the first (1) reaction. The metallic silver, as demonstrated in the second (2) reaction, is then undergone an oxidation to produce silver oxide (Ag2O) in the presence of an oxidizing agent. When silver oxide is interacted with water, as shown in the third (3) reaction, it undergoes ionization to produce silver ion (Ag+). Finally, as shown in the fourth reaction (4), when the silver ion interacts with the sulfhydryl group (−SH) of an enzyme, it forms a -SAg linkage, which effectively blocks the enzyme activity. Therefore, the antibacterial and antifungal activity of the NAGs appears to be even more prominent when the NAGs are in contact with water.
- The NAGs has a broad spectrum of antibacterial and antifungal activity. The NAGs of the present invention had bactericidal and fungicidal effects on more than twenty (20) common pathogens, which include, but are not limited to,Escherichia coli, Methicillin resistant Staphylococcus aureus, Chlamydia trachomatis, Providencia stuartii, Vibrio vulnificus, Pneumobacillus, Nitrate-negative bacillus, Staphylococcus aureus, Candida albicans, Bacillus cloacae, Bacillus allantoides, Morgan's bacillus (Salmonella morgani), Pseudomonas altophila, Arizona, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Bacillus subtilis, Bacillus foecalis alkaligenes, Streptococcus hemolyticus B, Citrobacter, Salmonella paratyphi C.
- Examples of the antibacterial activity of the NAGs were demonstrated in FIGS.1-3. FIG. 1 shows the effect of the NAGs on Staphylococcus aureus. The data demonstrate that within 8 hours of treatment with the NAGs, all of the S. aureus were killed. FIG. 2 shows the effect of the NAGs on Escherichia coli. The data also demonstrate that within 8 hours of treatment with the NAGs, all of the E. coli were killed. FIG. 3 shows the effect of the NAGs on Pseudomonas aeruginosa. The data show that within 12 hours of treatment with the NAGs, all of the P. aeruginosa were killed.
- The NAGs were prepared by first cutting the stalk marrow ofJuncus effuses L. into pieces of 0.5 to 2 cm at length. These small pieces of stalk marrow were washed, followed by boiling in water to remove any unwanted water soluble materials. The boiled stalk marrow pieces were than dried for later use. In the meantime, a nanosilver particles-containing solution was prepared by first dissolving AgNO3 in ammonia water, followed by adding glucose (as reducing agent) to the reaction solution. An oxidizing agent, preferably H2O2, was then added to the reaction solution. The quantity or volume of each of the ingredients used in the nanosilver particle-containing solution is listed in Table 1.
TABLE 1 The Nanosilver Particles-Containing Solution Ingredients Quantity or Volume AgNO3 15 Kg Ammonia Water 15 L Glucose 3 Kg Ethanol (95%) 5 L NaOH 0.5 Kg Oxidizing Agent (e.g., H2O2) 100 ml Distilled Water up to 1000 L - The above quantity of the nanosilver particles-containing solution was aimed at large scale industrial manufacturing use. The quantity could be scaled down proportionally for research and laboratory testing.
- FIG. 4 shows a flow chart of industrial production of the NAGs. The process was operated in the following chambers: (1) selection chamber; (2) separation chamber; (3) spraying chamber; (4) water removal chamber; (5) heat reaction chamber; (6) washing and soaking chamber; (7) drying chamber; and (8) grinding chamber.
- As shown in FIG. 4, in the “selection” chamber, stalk marrow ofJuncus effuses L. were cut into pieces, preferably at a length of about 0.5 to 2 cm. The small pieces of stalk marrow were sieved through a selection process and transferred to the “separation” chamber, where the stalk marrow pieces were boiled and dried. The small pieces of dried stalk marrow were then transferred to the “spraying” chamber where the nanosilver particles-containing solution was evenly sprayed and dispersed onto the small pieces of dried stalk marrow. The small pieces of stalk marrow were further soaked with the nanosilver particles-containing solution in the “spraying” chamber for an adequate amount of time. The small pieces of stalk marrow with attached nanosilver particles were then transferred to the “water removal” chamber where excess solution was removed from the pieces.
- The small pieces of stalk marrow were then transferred to the “heat reaction” chamber, where the nanosilver-attached stalk marrow pieces were treated with heat.
- The heat-reacted stalk marrow pieces were transferred to the “soaking and washing” chamber, where the pieces were soaked and washed first with hot water, then with cold water, to remove any unattached nanosilver particles and water-soluble substances. The washed nanosilver particles-attached stalk marrow pieces were then dried under heat in the “drying” chamber, and finally transferred to the “grinding” chamber to be ground to proper NAG sizes. The final NAGs should contain no water-soluble substances other than silver. These NAGs could be used in various healthcare, medicinal and industrial products to disinfect, inhibit the growth of bacteria or fungi, and/or prevent mold formation.
- Examples of the NAGs used in healthcare products include, but are not limited to, ointments, lotions, or spraying solutions for treating all kinds of injuries and/or bums, bacterial and fungal infections (including gynecological infections such as vaginitis), cleansing agents for clothing, women hygiene, acne or pimples, and soaking solution for tooth brush. Examples of the NAGs used in medicinal products include, but are not limited to, internal medicines for treating gastrointestinal bacterial infection, sexually transmitted diseases, or as an eye drop for treating eye diseases. Examples of the NAGs used in industrial products include, but are not limited to, food preservatives especially for fruits and vegetables, drinking water disinfectants, paper and construction filling materials preservation (especially to prevent mold formation).
- The following examples are illustrative, but not limiting the scope of the present invention. Reasonable variations, such as those occur to reasonable artisan, can be made herein without departing from the scope of the present invention.
- The content of the silver in the NAGs was analyzed by a titrimetric analysis as follows:
- A. Basic chemical reactions
- The basic chemical reactions involved in the volumetric analysis were:
- Ag++SCN−→AgSCN↓
- Fe+3+6SCN−→Fe(SCN)6 −3 (light brownish red)(end point)
- B. Preparation of solutions
- (1). Solvent: HNO3 solution. The solution was prepared by mixing nitric acid with water at ratio 1:1 (v/v). The concentration of nitric acid in the solution was 6N.
- (2). Indicator: 10% NH4Fe(SO4)2 aqueous solution (w/v).
- (3). Titrant: NH4SCN standardized solution.
- 0.75 g NH4SCN was weighed and dissolved in 1000 ml water in a volumetric flask. The flask was gently shaken to evenly distribute NH4SCN in the solution. The solution was standardized by a standard Ag solution.
- (4). Standard Ag solution:
- 1.0000 g of clean and dry silver shreds or flakes was weighed and cut into small pieces. The pieces were placed in a 1000 ml brown volumetric flask and completely dissolved in 100 ml 6 N HNO3 by heat in water bath. The flask was covered with filter paper during the heating process. After the flask cooled down, the volume of solution was brought up to 1000 ml by water. The flask was shaken to disperse the solute. The final concentration of the solution was 1 mg/ml.
- C. Standardizing NH4SCN solution
- Ten (10) ml of standard Ag solution (1 mg/ml) as shown in B(4) was measured and poured into a 200 ml volumetric flask. For the blank control, 10 ml of water was poured into the 200 ml volumetric flask. Then, 6N HNO3 was added to the flask (the acidic level of nitric acid was between 1-10%), followed by adding 1-2 ml of 10% NH4Fe(SO4)2 aqueous solution to the flask as the indicator. Water was then added along the wall of the flask until the volume was kept at 80-100 ml. NH4SCN solution prepared in B(3) was used as titrant to react with silver solution until a stable light brownish red appeared, which signaled the end of the reaction. The titrimetric analysis was conducted in triplicates to get a mean value. The standard deviation (SD) of the mean values should be less than 0.10 ml. The silver titer value, TAg, was calculated:
- TAg=Ag amount in Ag standard solution/[(mean volume of the triplicates)-blank](The unit for TAg is mg/ml.)
- D. Titrimetric analysis of the NAGs
- 100.0 mg of the NAGs, after being dried in a desiccator for 2 to 4 hours, was precisely measured and placed in a 200 ml flask. Then, 20-30 ml of 6N HNO3 were added into the flask, and the flask was placed on a low-heat thermoelectrical plate until the solution was slightly boiling, where the solution was maintained at this stage until the solution became colorless. Then, the flask was cooled down and diluted to 100 ml. 1-2 ml indicator was added to the solution. The solution was analyzed by titration using the standardized NH4SCN solution. When the solution was stable in a color of light brownish red, it was the end point of the titration.
- E. Results
- The content of the silver in the NAGs was calculated by the following equation.
- Ag% in the NAGs=(V×T Ag /W)×100%
- Where V was the volume of the NH4SCN solution added to the titration flask after the blank was deducted. TAg was in the unit of mg Ag/ml. W was the weight of the NAG sample in mg.
- From the above calculation, the silver content of the NAGs was about 2-8%.
- The antibacterial effect of the NAGs in the solution was tested as follows:
- A. Preparation of the NAGs solution
- Five (5) g of the NAGs were suspended in 500 ml of water and stayed in the solution for 24 hrs to obtain an NAGs-containing solution.
- B. Preparation of bacteria
- M-H liquid and solid culture media were used for activation and culture of the bacteria.Staphylococcus aureus stock M120, Escherichia coli stock E109, and Pseudomonas aeruginosa stock PS208 were used for the testing. These stocks were provided by the Microbiology Teaching and Research Section at Henan Medical University.
- The frozen stocks of bacteria were seeded onto solid culture media. Single colonies were picked and inoculated respectively in 2 ml liquid culture medium and cultured at 37° C. for eight (8) hours. Then, the liquid culture medium was diluted at 1:1000 and stored in refrigerator (around 0° C.) until ready for use. The solution contained about 105 CFU/ml bacterial stock.
- C. Treatment of bacterial stocks in the solution
- Under sterile condition, the NAGs-containing solution was added to three (3) flasks, each containing 100 ml of the solution. One (1) ml of the bacterial stocks ofE. coli, S. aureus, or P. aeruginosa was then added to the three flasks, respectively. The control was prepared by adding the bacterial stocks in the flasks containing water. The inhibitory effect of the NAGs on the three different bacteria was conducted over a period of eight (8) hours.
- D. Results of the experiment
- At the end of the eight hours study, the solution was diluted and plated on a culture plate to measure the number of remaining bacteria. In the solution containing the NAGs, more than 99% of all the tested bacteria were killed, which demonstrated that the NAGs-containing solution was very effective as bactericide and could be used as disinfectant.
- A time course study of the antibacterial effects of the NAGs in a solution was conducted as follows:
- A. Preparation of bacterial stocks
- M-H liquid and solid culture media were used for activation and culture of the bacteria.Staphylococcus aureus stock M120, Escherichia coli stock E109, and Pseudomonas aeruginosa stock PS208 were provided by the Microbiology Teaching and Research Section at Henan Medical University. The stocks were cultured in an incubator at 37° C. for 24 hours.
- The frozen stocks of bacteria were seeded to a culture plate. Single colonies were chosen and inoculated in 2 ml liquid culture medium, respectively, where they were cultured at 37° C. for eight (8) hours. Then, the liquid culture medium was diluted at 1:1000 and stored in the refrigerator (around 0° C.) until ready for use. The solution contained about 105 CFU/ml bacterial stock.
- B. The effect of the NAGs onE. coli, S. aureus, and P. aeruginosa
- Under sterile condition, three (3) flasks, which contained 100 ml of the NAGs-containing solution in each flask, were inoculated withE. coli, S. aureus, or P. aeruginosa, respectively, with about 104-105 bacteria per ml in the solution. A time course was studied at 2, 4, 8, 12, and 24 hours intervals, each with 0.5 ml of sample. The viable number of the bacteria was counted. The control study was conducted with the same number of bacteria incubated at the same condition in a 100 ml of water rather than the NAGs-containing solution.
- C. Results
- As shown in FIG. 1, after inoculatingS. aureus in a solution containing the NAGs, the number of S. aureus reduced to 0.01% of the starting number during the first two hours after the inoculation. Eight (8) hours after the inoculation, all of the bacteria were killed.
- As shown in FIG. 2, after inoculatingE. coli in a solution containing the NAGs, the number of E. coli reduced to 0.1% of the starting number during the first two hours after the inoculation. Eight (8) hours after the inoculation, all of the bacteria were killed.
- As shown in FIG. 3, after inoculatingP. aeruginosai in a solution containing the NAGs, the number of E. coli reduced to 1% of the starting number during the first two hours after the inoculation. Twelve (12) hours after the inoculation, all of the bacteria were killed
- The results of this study indicate that the NAGs had inhibitory effects onE. coli, S. aureus, and P. aeruginosa.
- The antibacterial effect of the NAGs was tested on toothbrush as follows:
- A. Preparation of bacteria
- M-H liquid and solid culture media were used for activation and culture of the bacteria.Staphylococcus aureus stock M120 was provided by the Microbiology Teaching and Research Section at Henan Medical University. The stock was cultured in an incubator at 37° C. for 24 hours.
- The frozen stock of bacteria was seeded to a culture plate. A single colony was chosen and inoculated in 2 ml liquid culture medium, respectively, where the bacteria were cultured at 37° C. for eight (8) hours. Then, the liquid culture medium was diluted at 1:1000 and stored in the refrigerator (around 0° C.) until ready for use. The solution contained about 105 CFU/ml bacterial stock.
- B. Treatment of toothbrush
- The bactericidal activity of the NAGs on toothbrush was tested by two (2) methods:
- (1). Treatment of toothbrush in its natural state
- A half of a toothbrush was immersed in 30 ml of a solution containing the NAGs for eight (8) hours. The other half of the toothbrush was immersed in 30 ml of saline solution. One (1) ml of each of the solutions was taken out after the 8 hours incubation, diluted, and tested for bacteria counts on plate. This method tested the natural existence of germs on the toothbrush and the effect of the NAGs on inhibiting the growth of the germs.
- (2). Treatment of toothbrush in use with addedStaphylococcus aureus
- A half of the toothbrush was immersed in 30 ml solution containing the NAGs. One (1) ml of the bacterial stock containingStaphylococcus aureus was added to the solution. At the end of the 8 hours incubation, 1 ml of the solution was taken out and tested for bacteria counts on plate. The other half of the toothbrush was immersed in 30 ml of saline solution. One (1) ml of each of the solutions was taken out after the 8 hours incubation, diluted, and tested for bacteria counts on plate. This method tested the bactericidal effect of the NAGs on toothbrush where known amount of S. aureus was inoculated in the solution
- C. Results
- (1). Treatment of toothbrush in its natural state
- The bactericidal efficiency for the NAGs was about 95%.
- (2). Treatment of toothbrush in use with addedStaphylococcus aureus
- The bactericidal efficiency for the NAGs was about 98%.
- The results show that the NAGs were effective against bacteria which were grown on the toothbrush. Therefore, the NAGs could be effectively used as a disinfectant for toothbrush.
- The NAGs were given to normal, healthy rats in a dose of 925 mg/kg of body weight per day for fourteen (14) days. This dose was more than 4,625 fold of the dose generally recommended to humans. The activities of rats were monitored. At the end of the 14 days period, no rats were dead or sick, which indicated that the NAGs were safe and non-toxic to rats.
- A 5% (w/v) NAGs-containing solution was applied to the skin of the rabbits. The rabbits were monitored at 1 hr, 24 hrs, and 48 hrs intervals. No rash, bruise, or any irritating reaction was observed on the rabbit skins, which indicated that the NAGs were safe and not creating any allergic reaction on the skins.
- While the invention has been described by way of examples and in terms of the preferred embodiments, it is to be understood that the invention is not limited to the disclosed embodiments. On the contrary, it is intended to cover various modifications as would be apparent to those skilled in the art. Therefore, the scope of the appended claims should be accorded the broadest interpretation so as to encompass all such modifications.
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/840,906 US6379712B1 (en) | 2000-09-13 | 2001-04-25 | Nanosilver-containing antibacterial and antifungal granules and methods for preparing and using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23092500P | 2000-09-13 | 2000-09-13 | |
US09/840,906 US6379712B1 (en) | 2000-09-13 | 2001-04-25 | Nanosilver-containing antibacterial and antifungal granules and methods for preparing and using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
US6379712B1 US6379712B1 (en) | 2002-04-30 |
US20020051823A1 true US20020051823A1 (en) | 2002-05-02 |
Family
ID=26924689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/840,906 Expired - Lifetime US6379712B1 (en) | 2000-09-13 | 2001-04-25 | Nanosilver-containing antibacterial and antifungal granules and methods for preparing and using the same |
Country Status (1)
Country | Link |
---|---|
US (1) | US6379712B1 (en) |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030203046A1 (en) * | 2000-07-27 | 2003-10-30 | Burrell Robert E. | Solutions and aerosols of metal-containing compounds |
WO2004074388A1 (en) * | 2003-02-18 | 2004-09-02 | Otto Schildhauer | Method for treating tubular goods |
US20040180093A1 (en) * | 2003-03-12 | 2004-09-16 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US20040191329A1 (en) * | 2000-07-27 | 2004-09-30 | Burrell Robert E. | Compositions and methods of metal-containing materials |
EP1481783A2 (en) * | 2003-05-31 | 2004-12-01 | Daewoo Electronics Corporation | Method for producing an injection-molded material with an antibacterial function |
WO2005000324A3 (en) * | 2003-06-03 | 2005-03-24 | American Biotech Labs | Colloidal silver composition having antimicrobial properties |
US20050061678A1 (en) * | 1999-06-01 | 2005-03-24 | American Biotech Labs | Treatment of humans with colloidal silver composition |
US20050123621A1 (en) * | 2003-12-05 | 2005-06-09 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
US20050124724A1 (en) * | 2003-12-05 | 2005-06-09 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US20060035039A1 (en) * | 2004-08-12 | 2006-02-16 | 3M Innovative Properties Company | Silver-releasing articles and methods of manufacture |
US20060034899A1 (en) * | 2004-08-12 | 2006-02-16 | Ylitalo Caroline M | Biologically-active adhesive articles and methods of manufacture |
US20060147502A1 (en) * | 2004-12-30 | 2006-07-06 | Kimberly-Clark Worldwide, Inc. | Methods for controlling microbial pathogens on currency and mail |
US20060233889A1 (en) * | 2005-04-14 | 2006-10-19 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
EP1779855A1 (en) * | 2005-10-28 | 2007-05-02 | Abdula Kurkayev | Nanoparticles of a heterocrystal mineral for use as a medicament and method of producing the same |
US20070098806A1 (en) * | 2002-05-02 | 2007-05-03 | Ismail Ashraf A | Polymer-Based Antimicrobial Agents, Methods of Making Said Agents, and Products Incorporating Said Agents |
US20070166399A1 (en) * | 2006-01-13 | 2007-07-19 | 3M Innovative Properties Company | Silver-containing antimicrobial articles and methods of manufacture |
US20070190174A1 (en) * | 1999-06-01 | 2007-08-16 | American Silver Llc | Antiviral Colloidal Silver Composition |
EP1880213A2 (en) * | 2005-01-05 | 2008-01-23 | Robert Holladay | Silver/water, silver gels and silver-based compositions; and methods for making and using the same |
US20080085326A1 (en) * | 2006-10-04 | 2008-04-10 | Hai Xiong Ruan | Antimicrobial material compositions enriched with different active oxygen species |
US20080213328A1 (en) * | 2007-03-02 | 2008-09-04 | Yao-Nien Chung | Nanosilver-containing preservation articles, and the preparation process and the uses thereof |
US7445799B1 (en) | 2000-06-21 | 2008-11-04 | Icet, Inc. | Compositions for microbial and chemical protection |
US20090047475A1 (en) * | 2007-08-17 | 2009-02-19 | Sun Mi Jeon | Composition for coating wiper blade rubbers, coating method using the same, and wiper blade rubbers made therefrom |
US20090130161A1 (en) * | 2000-06-21 | 2009-05-21 | Icet, Inc. | Material compositions for microbial and chemical protection |
US20100098949A1 (en) * | 2006-10-18 | 2010-04-22 | Burton Scott A | Antimicrobial articles and method of manufacture |
US20100137822A1 (en) * | 2007-02-15 | 2010-06-03 | Huaide Chen | Far infrared anion complex sanitary napkin/pad |
US20110123584A1 (en) * | 2009-11-20 | 2011-05-26 | Jeffery Richard Seidling | Temperature Change Compositions and Tissue Products Providing a Cooling Sensation |
US20110123578A1 (en) * | 2009-11-20 | 2011-05-26 | Wenzel Scott W | Cooling Substrates With Hydrophilic Containment Layer and Method of Making |
US8795717B2 (en) | 2009-11-20 | 2014-08-05 | Kimberly-Clark Worldwide, Inc. | Tissue products including a temperature change composition containing phase change components within a non-interfering molecular scaffold |
WO2016161348A1 (en) * | 2015-04-01 | 2016-10-06 | Attostat, Inc. | Nanoparticle compositions and methods for treating or preventing tissue infections and diseases |
US10137503B2 (en) | 2011-07-01 | 2018-11-27 | Attostat, Inc. | Method and apparatus for production of uniformly sized nanoparticles |
US10201571B2 (en) | 2016-01-25 | 2019-02-12 | Attostat, Inc. | Nanoparticle compositions and methods for treating onychomychosis |
US10774429B2 (en) | 2015-04-13 | 2020-09-15 | Attostat, Inc. | Anti-corrosion nanoparticle compositions |
US11018376B2 (en) | 2017-11-28 | 2021-05-25 | Attostat, Inc. | Nanoparticle compositions and methods for enhancing lead-acid batteries |
US11473202B2 (en) | 2015-04-13 | 2022-10-18 | Attostat, Inc. | Anti-corrosion nanoparticle compositions |
CN115227718A (en) * | 2022-08-04 | 2022-10-25 | 广东省农业科学院动物卫生研究所 | Application of nano-silver in inhibiting streptococcus suis |
US11646453B2 (en) | 2017-11-28 | 2023-05-09 | Attostat, Inc. | Nanoparticle compositions and methods for enhancing lead-acid batteries |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030185889A1 (en) * | 2002-03-27 | 2003-10-02 | Jixiong Yan | Colloidal nanosilver solution and method for making the same |
US6979491B2 (en) * | 2002-03-27 | 2005-12-27 | Cc Technology Investment Co., Ltd. | Antimicrobial yarn having nanosilver particles and methods for manufacturing the same |
US6924325B2 (en) * | 2002-06-21 | 2005-08-02 | Kerr Corporation | Silver-containing dental composition |
KR100656169B1 (en) * | 2002-12-23 | 2006-12-12 | 삼성전자주식회사 | Method for Producing A Stuff Having Bacillus Resistance on The Surface Thereof by Nano Size Metal |
CA2678624C (en) * | 2003-05-16 | 2012-11-06 | Exciton Technologies Inc. | Deposition products, composite materials and processes for the production thereof |
US7462590B2 (en) * | 2005-02-25 | 2008-12-09 | Solutions Biomed, Llc | Aqueous disinfectants and sterilants comprising a peroxide/peracid/transition metal mixture |
US7511007B2 (en) * | 2005-02-25 | 2009-03-31 | Solutions Biomed, Llc | Aqueous sanitizers, disinfectants, and/or sterilants with low peroxygen content |
US7553805B2 (en) * | 2005-02-25 | 2009-06-30 | Solutions Biomed, Llc | Methods and compositions for treating viral, fungal, and bacterial infections |
US7473675B2 (en) * | 2005-02-25 | 2009-01-06 | Solutions Biomed, Llc | Disinfectant systems and methods comprising a peracid, alcohol, and transition metal |
WO2006093792A1 (en) | 2005-02-25 | 2006-09-08 | Solutions Biomed, Llc | Aqueous disinfectants and sterilants |
US7504369B2 (en) * | 2005-02-25 | 2009-03-17 | Solutions Biomed, Llc | Methods and compositions for decontaminating surfaces exposed to chemical and/or biological warfare compounds |
US7534756B2 (en) * | 2005-02-25 | 2009-05-19 | Solutions Biomed, Llc | Devices, systems, and methods for dispensing disinfectant solutions comprising a peroxygen and transition metal |
US7507701B2 (en) * | 2005-02-25 | 2009-03-24 | Solutions Biomed, Llc | Aqueous disinfectants and sterilants including transition metals |
KR100767714B1 (en) | 2005-04-19 | 2007-10-19 | 양원동 | Nano silver conation metal tooth dental caries make good |
US7381686B2 (en) * | 2005-04-27 | 2008-06-03 | Taikong Corp. | Composite for inhibiting algae growth and use therof |
US20060254988A1 (en) * | 2005-05-10 | 2006-11-16 | Confirm Monitoring Systems, Inc. | Methods and compositions for the treatment of water |
US8119548B2 (en) * | 2005-05-18 | 2012-02-21 | Building Materials Investment Corporation | Nanosilver as a biocide in building materials |
TWM286648U (en) * | 2005-10-06 | 2006-02-01 | Wu-Lang Jang | Toothbrush receptacle with disinfection function |
US20070154506A1 (en) * | 2005-12-30 | 2007-07-05 | Patton David L | Antimicrobial agent to inhibit the growth of microorganisms on disposable products |
US20070154505A1 (en) * | 2005-12-30 | 2007-07-05 | Manico Joseph A | Antimicrobial agent to inhibit the growth of microorganisms on building materials |
US20070161936A1 (en) * | 2006-01-06 | 2007-07-12 | Svetlik Harvey E | Wound treatment-dressing and method of manufacture |
KR100788997B1 (en) * | 2006-03-10 | 2007-12-28 | 김주영 | Method For Preparing Silver Bonded Antimicrobial Moist Wound Dressing And The Moist Wound Dressing |
US8367089B2 (en) * | 2006-04-24 | 2013-02-05 | Axcelon Biopolymers Corporation | Nanosilver coated bacterial cellulose |
US7661430B2 (en) * | 2006-05-19 | 2010-02-16 | Richard Mason | Antimicrobial dental appliances including mouthguards and mouthpieces |
US20070286878A1 (en) * | 2006-06-07 | 2007-12-13 | Harruna Issifu I | Removable films for sanitizing substrates and methods of use thereof |
AU2007271357B2 (en) * | 2006-07-05 | 2013-07-04 | Janssen Pharmaceutica N.V. | Method for producing metal nanoparticles |
US7635552B2 (en) * | 2006-07-25 | 2009-12-22 | Endicott Interconnect Technologies, Inc. | Photoresist composition with antibacterial agent |
WO2008036225A2 (en) | 2006-09-20 | 2008-03-27 | Entek Manufacturing, Inc. | Conformable structured therapeutic dressing |
WO2008130433A2 (en) * | 2006-10-12 | 2008-10-30 | C-3 International, Llc | Methods for providing prophylactic surface treatment for fluid processing systems and components thereof |
US7892317B2 (en) * | 2007-07-11 | 2011-02-22 | Jafar Rahman Nia | Preparation of colloidal nanosilver |
WO2009032203A1 (en) * | 2007-08-30 | 2009-03-12 | Solutions Biomed, Llc | Colloidal metal-containing skin sanitizer |
GB0800081D0 (en) * | 2008-01-04 | 2008-02-13 | Univ Gent | Silver nanoparticles with specific surface area and/or isoelectric point and a method for producing them |
WO2009114754A1 (en) * | 2008-03-14 | 2009-09-17 | Solutions Biomed, Llc | Multi-chamber container system for storing and mixing fluids |
US8623301B1 (en) | 2008-04-09 | 2014-01-07 | C3 International, Llc | Solid oxide fuel cells, electrolyzers, and sensors, and methods of making and using the same |
US8716339B2 (en) * | 2008-11-12 | 2014-05-06 | Solutions Biomed, Llc | Two-part disinfectant system and related methods |
US20100120913A1 (en) * | 2008-11-12 | 2010-05-13 | Larson Brian G | Resin catalyzed and stabilized peracid compositions and associated methods |
US8789716B2 (en) * | 2008-11-12 | 2014-07-29 | Solutions Biomed, Llc | Multi-chamber container system for storing and mixing liquids |
US20120195838A1 (en) * | 2009-09-04 | 2012-08-02 | National University Corporation Kumamoto University | Oral composition for denture wearers |
CA2789281C (en) | 2010-02-10 | 2015-11-24 | C3 International, Llc | Low temperature electrolytes for solid oxide cells having high ionic conductivity |
CN102895315B (en) * | 2012-09-28 | 2014-02-26 | 南昌大学 | Nano-silver bacteriostatic composition containing fructus forsythiae extracting solution |
CN103044611B (en) * | 2012-12-17 | 2015-06-10 | 上海师范大学 | Preparation of polymer antibacterial nano-particles and magnetic antibacterial nano-particles containing halamine functional groups |
US9446079B2 (en) | 2013-07-11 | 2016-09-20 | Links Medical Products, Incorporated | Honey and silver nitrate composition, composition dressing and methods of making same |
WO2015009618A1 (en) | 2013-07-15 | 2015-01-22 | Fcet, Llc | Low temperature solid oxide cells |
TWI565853B (en) | 2015-05-11 | 2017-01-11 | Acelon Chem & Fiber Corp | Preparation of nano - silver blended natural cellulose melt - blown non - woven |
TWI551739B (en) | 2015-05-11 | 2016-10-01 | Acelon Chem & Fiber Corp | Method for preparing nano silver blended natural cellulose spunbonded non-woven fabric |
TWI565852B (en) | 2015-05-11 | 2017-01-11 | Acelon Chem & Fiber Corp | Preparation of Nano silver blended natural cellulose fibers method |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4828832A (en) | 1983-09-07 | 1989-05-09 | Laboratorios Biochemie De Mexico | Method of manufacturing a composition for treating skin lesions |
EP0695501B1 (en) | 1994-08-01 | 2001-05-30 | Maruwa KCK Co., Ltd. | Metallic bactericidal agent |
JP3121503B2 (en) | 1994-10-18 | 2001-01-09 | レンゴー株式会社 | Antibacterial agent |
US5973050A (en) | 1996-07-01 | 1999-10-26 | Integrated Cryoelectronic Inc. | Composite thermoelectric material |
US5785972A (en) | 1997-01-10 | 1998-07-28 | Tyler; Kathleen A. | Colloidal silver, honey, and helichrysum oil antiseptic composition and method of application |
-
2001
- 2001-04-25 US US09/840,906 patent/US6379712B1/en not_active Expired - Lifetime
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060182813A1 (en) * | 1999-06-01 | 2006-08-17 | Holladay Robert J | Colloidal silver composition having microbial properties |
US20070190174A1 (en) * | 1999-06-01 | 2007-08-16 | American Silver Llc | Antiviral Colloidal Silver Composition |
US8753691B2 (en) * | 1999-06-01 | 2014-06-17 | American Silver, Llc | Antiviral colloidal silver composition |
US8535728B2 (en) * | 1999-06-01 | 2013-09-17 | American Silver, Llc | Colloidal silver composition having antimicrobial properties |
US20050061678A1 (en) * | 1999-06-01 | 2005-03-24 | American Biotech Labs | Treatment of humans with colloidal silver composition |
US7135195B2 (en) * | 1999-06-01 | 2006-11-14 | American Silver, Llc | Treatment of humans with colloidal silver composition |
US20090130161A1 (en) * | 2000-06-21 | 2009-05-21 | Icet, Inc. | Material compositions for microbial and chemical protection |
US7445799B1 (en) | 2000-06-21 | 2008-11-04 | Icet, Inc. | Compositions for microbial and chemical protection |
US8192765B2 (en) | 2000-06-21 | 2012-06-05 | Icet, Inc. | Material compositions for microbial and chemical protection |
US20030203046A1 (en) * | 2000-07-27 | 2003-10-30 | Burrell Robert E. | Solutions and aerosols of metal-containing compounds |
US20040191329A1 (en) * | 2000-07-27 | 2004-09-30 | Burrell Robert E. | Compositions and methods of metal-containing materials |
US7951853B2 (en) | 2002-05-02 | 2011-05-31 | Smart Anti-Microbial Solutions, Llc | Polymer-based antimicrobial agents, methods of making said agents, and products incorporating said agents |
US20070098806A1 (en) * | 2002-05-02 | 2007-05-03 | Ismail Ashraf A | Polymer-Based Antimicrobial Agents, Methods of Making Said Agents, and Products Incorporating Said Agents |
US20060018967A1 (en) * | 2003-02-18 | 2006-01-26 | Otto Schildhauer | Method for treating pipelines |
WO2004074388A1 (en) * | 2003-02-18 | 2004-09-02 | Otto Schildhauer | Method for treating tubular goods |
US20040180093A1 (en) * | 2003-03-12 | 2004-09-16 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
EP1481783A3 (en) * | 2003-05-31 | 2005-11-23 | Daewoo Electronics Corporation | Method for producing an injection-molded material with an antibacterial function |
EP1481783A2 (en) * | 2003-05-31 | 2004-12-01 | Daewoo Electronics Corporation | Method for producing an injection-molded material with an antibacterial function |
US20040239004A1 (en) * | 2003-05-31 | 2004-12-02 | Kim Jin Soo | Method for producing an injection-molded material with an antibacterial function |
WO2005000324A3 (en) * | 2003-06-03 | 2005-03-24 | American Biotech Labs | Colloidal silver composition having antimicrobial properties |
US7745509B2 (en) | 2003-12-05 | 2010-06-29 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
EP1689456B1 (en) * | 2003-12-05 | 2012-02-22 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US20100233273A1 (en) * | 2003-12-05 | 2010-09-16 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US8193267B2 (en) | 2003-12-05 | 2012-06-05 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US20050124724A1 (en) * | 2003-12-05 | 2005-06-09 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US20050123621A1 (en) * | 2003-12-05 | 2005-06-09 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
US20060034899A1 (en) * | 2004-08-12 | 2006-02-16 | Ylitalo Caroline M | Biologically-active adhesive articles and methods of manufacture |
US20060035039A1 (en) * | 2004-08-12 | 2006-02-16 | 3M Innovative Properties Company | Silver-releasing articles and methods of manufacture |
US20060147502A1 (en) * | 2004-12-30 | 2006-07-06 | Kimberly-Clark Worldwide, Inc. | Methods for controlling microbial pathogens on currency and mail |
EP1880213A4 (en) * | 2005-01-05 | 2010-06-23 | Robert Holladay | Silver/water, silver gels and silver-based compositions; and methods for making and using the same |
EP1880213A2 (en) * | 2005-01-05 | 2008-01-23 | Robert Holladay | Silver/water, silver gels and silver-based compositions; and methods for making and using the same |
US8399027B2 (en) | 2005-04-14 | 2013-03-19 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
US20060233889A1 (en) * | 2005-04-14 | 2006-10-19 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
US20090226526A1 (en) * | 2005-10-28 | 2009-09-10 | Abdula Kurkayev | Nanoparticles of a heterocrystal mineral for use as a medicament and method of producing the same |
WO2007048634A2 (en) | 2005-10-28 | 2007-05-03 | Abdula Kurkayev | Nanoparticles of a heterocrystal mineral for use as a medicament and method of producing the same |
EP1779855A1 (en) * | 2005-10-28 | 2007-05-02 | Abdula Kurkayev | Nanoparticles of a heterocrystal mineral for use as a medicament and method of producing the same |
WO2007048634A3 (en) * | 2005-10-28 | 2007-12-06 | Abdula Kurkayev | Nanoparticles of a heterocrystal mineral for use as a medicament and method of producing the same |
US20070166399A1 (en) * | 2006-01-13 | 2007-07-19 | 3M Innovative Properties Company | Silver-containing antimicrobial articles and methods of manufacture |
US20080279960A1 (en) * | 2006-01-13 | 2008-11-13 | Burton Scott A | Silver-Containing Antimicrobial Articles and Methods of Manufacture |
US9289450B2 (en) | 2006-01-13 | 2016-03-22 | 3M Innovative Properties Company | Silver-containing antimicrobial articles and methods of manufacture |
US8192764B2 (en) | 2006-01-13 | 2012-06-05 | 3M Innovative Properties Company | Silver-containing antimicrobial articles and methods of manufacture |
US20080085326A1 (en) * | 2006-10-04 | 2008-04-10 | Hai Xiong Ruan | Antimicrobial material compositions enriched with different active oxygen species |
US20100098949A1 (en) * | 2006-10-18 | 2010-04-22 | Burton Scott A | Antimicrobial articles and method of manufacture |
AU2008215041B9 (en) * | 2007-02-15 | 2014-01-16 | Shenzhen Yuelang Techno-Industrial Co., Ltd. | A far-infrared anion compound sanitary napkin and pad |
AU2008215041B2 (en) * | 2007-02-15 | 2013-09-12 | Shenzhen Yuelang Techno-Industrial Co., Ltd. | A far-infrared anion compound sanitary napkin and pad |
US20100137822A1 (en) * | 2007-02-15 | 2010-06-03 | Huaide Chen | Far infrared anion complex sanitary napkin/pad |
US20080213328A1 (en) * | 2007-03-02 | 2008-09-04 | Yao-Nien Chung | Nanosilver-containing preservation articles, and the preparation process and the uses thereof |
US8304068B2 (en) * | 2007-08-17 | 2012-11-06 | Adm21 Co., Ltd. | Composition for coating wiper blade rubbers, coating method using the same, and wiper blade rubbers made therefrom |
US20090047475A1 (en) * | 2007-08-17 | 2009-02-19 | Sun Mi Jeon | Composition for coating wiper blade rubbers, coating method using the same, and wiper blade rubbers made therefrom |
US9181465B2 (en) | 2009-11-20 | 2015-11-10 | Kimberly-Clark Worldwide, Inc. | Temperature change compositions and tissue products providing a cooling sensation |
US8795717B2 (en) | 2009-11-20 | 2014-08-05 | Kimberly-Clark Worldwide, Inc. | Tissue products including a temperature change composition containing phase change components within a non-interfering molecular scaffold |
US8894814B2 (en) | 2009-11-20 | 2014-11-25 | Kimberly-Clark Worldwide, Inc. | Cooling substrates with hydrophilic containment layer and method of making |
US20110123578A1 (en) * | 2009-11-20 | 2011-05-26 | Wenzel Scott W | Cooling Substrates With Hydrophilic Containment Layer and Method of Making |
US20110123584A1 (en) * | 2009-11-20 | 2011-05-26 | Jeffery Richard Seidling | Temperature Change Compositions and Tissue Products Providing a Cooling Sensation |
US9545365B2 (en) | 2009-11-20 | 2017-01-17 | Kimberly-Clark Worldwide, Inc. | Temperature change compositions and tissue products providing a cooling sensation |
US8480852B2 (en) | 2009-11-20 | 2013-07-09 | Kimberly-Clark Worldwide, Inc. | Cooling substrates with hydrophilic containment layer and method of making |
US10137503B2 (en) | 2011-07-01 | 2018-11-27 | Attostat, Inc. | Method and apparatus for production of uniformly sized nanoparticles |
US10610934B2 (en) | 2011-07-01 | 2020-04-07 | Attostat, Inc. | Method and apparatus for production of uniformly sized nanoparticles |
WO2016161348A1 (en) * | 2015-04-01 | 2016-10-06 | Attostat, Inc. | Nanoparticle compositions and methods for treating or preventing tissue infections and diseases |
US10953043B2 (en) | 2015-04-01 | 2021-03-23 | Attostat, Inc. | Nanoparticle compositions and methods for treating or preventing tissue infections and diseases |
US11473202B2 (en) | 2015-04-13 | 2022-10-18 | Attostat, Inc. | Anti-corrosion nanoparticle compositions |
US10774429B2 (en) | 2015-04-13 | 2020-09-15 | Attostat, Inc. | Anti-corrosion nanoparticle compositions |
US10201571B2 (en) | 2016-01-25 | 2019-02-12 | Attostat, Inc. | Nanoparticle compositions and methods for treating onychomychosis |
US11018376B2 (en) | 2017-11-28 | 2021-05-25 | Attostat, Inc. | Nanoparticle compositions and methods for enhancing lead-acid batteries |
US11646453B2 (en) | 2017-11-28 | 2023-05-09 | Attostat, Inc. | Nanoparticle compositions and methods for enhancing lead-acid batteries |
CN115227718A (en) * | 2022-08-04 | 2022-10-25 | 广东省农业科学院动物卫生研究所 | Application of nano-silver in inhibiting streptococcus suis |
Also Published As
Publication number | Publication date |
---|---|
US6379712B1 (en) | 2002-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6379712B1 (en) | Nanosilver-containing antibacterial and antifungal granules and methods for preparing and using the same | |
RU2422137C1 (en) | Method of obtaining biocidal polyguanidine and biocidal polyguanidine | |
US20100003296A1 (en) | Manufacturing methods and applications of antimicrobial plant fibers having silver particles | |
EP1490543B1 (en) | Antimicrobial yarn having nanosilver particles and methods for manufacturing the same | |
CN101389221B (en) | Silver/water, silver gels and silver-based compositions, method for fabricating and using the same | |
US20180168165A1 (en) | Silver iodate compounds having antimicrobial properties | |
WO2003080231A1 (en) | Colloidal nanosilver solution and method for making the same | |
WO2014012171A1 (en) | Anti-microbial gel formulations containing a silver (i) periodate | |
RU2407289C1 (en) | Nanostructured biocide composition | |
US9723843B2 (en) | Family of silver (I) periodate compounds having broad microbial properties | |
KR20130010880A (en) | Antiseptic ointment comprising bentonite intercalated with silver, copper or zinc for external application | |
WO2001072642A1 (en) | Silver ion-containing solution and use thereof | |
CN1082645A (en) | Long-acting broad-spectrum antiseptic fabric and preparation method thereof | |
RU2408755C1 (en) | Composition for antiseptic treatment of woven materials | |
KR20060109295A (en) | Nano polymer-silica-silver | |
EP2170081B1 (en) | Antimicrobial compositions | |
CN100334292C (en) | Nanometer silver antiseptic yarn and its production process | |
Kareem et al. | Evaluation of inhibition activity of silver nanoparticles activity against pathogenic bacteria | |
US11000502B2 (en) | Antimicrobial compositions comprising copper-hydroxypyrone complexes | |
RU2426560C1 (en) | Composition for antiseptic processing woven materials | |
CN108938559B (en) | DNA gel sterilization material, preparation method thereof and application of DNA gel sterilization material as sterilization material | |
JP2005002033A (en) | Antimicrobial and degerming agent | |
KR200391561Y1 (en) | Silver Nano Banban Line | |
CN115919892A (en) | Preparation method for obtaining two pathogenic bacteria bacteriostatic complexes, two pathogenic bacteria bacteriostatic complexes and application thereof | |
WO2023131855A1 (en) | Antimicrobial composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GLOBOASIA L.L.C., MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YAN, JIXIONG;CHENG, JIACHONG;REEL/FRAME:011738/0953 Effective date: 20010420 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: LEGEND WIN FINANCE CORPORATION, VIRGIN ISLANDS, BR Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GLOBOASIA, LLC;REEL/FRAME:013531/0503 Effective date: 20021125 |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 8 |
|
SULP | Surcharge for late payment |
Year of fee payment: 7 |
|
FPAY | Fee payment |
Year of fee payment: 12 |